Stallergenes S.A. - Product Pipeline Review - 2012 - This pharmaceuticals report, "Stallergenes S.A. - Product Pipeline Review - 2012" provides data on the Stallergenes S.A.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Stallergenes S.A.'s corporate website, SEC filings, investor presentations and featured press releases, both from Stallergenes S.A. and industry-specific third party sources, put together by This team.
Scope
- Stallergenes S.A. - Brief Stallergenes S.A. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Stallergenes S.A. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Stallergenes S.A. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Stallergenes S.A.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Stallergenes S.A.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Stallergenes S.A. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Stallergenes S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Stallergenes S.A..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Stallergenes S.A. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Stallergenes S.A.; Stallergenes S.A. - Key Therapeutics; Stallergenes S.A. - Pipeline Overview and Promising Molecules; Stallergenes S.A. - News; Stallergenes S.A. - Latest Updates; Stallergenes S.A. - Pipeline; Stallergenes S.A. - Discontinued/Dormant Projects
Table of Contents
Table of Contents
List of Tables
List of Figures
Stallergenes S.A. Snapshot
Stallergenes S.A. Overview
Key Information
Key Facts
Stallergenes S.A. - Research and Development Overview
Key Therapeutic Areas
Stallergenes S.A. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Stallergenes S.A. - Pipeline Products Glance
Stallergenes S.A. - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Stallergenes S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Stallergenes S.A. - Drug Profiles
ACTAIR
Product Description
Mechanism of Action
R&D Progress
Japanese Cedar Pollen Tablet
Product Description
Mechanism of Action
R&D Progress
Oralair
Product Description
Mechanism of Action
R&D Progress
Ragweed Sublingual Immunotherapy Tablet
Product Description
Mechanism of Action
R&D Progress
rBet v1
Product Description
Mechanism of Action
R&D Progress
Staloral
Product Description
Mechanism of Action
R&D Progress
Stallergenes S.A. - Pipeline Products by Route of Administration
Stallergenes S.A. - Recent Pipeline Updates
Stallergenes S.A. - Dormant Projects
Stallergenes S.A. - Company Statement
Stallergenes S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Stallergenes S.A., Recent Developments
Stallergenes S.A.- Press Release
May 30, 2012: Stallergenes Launches Oralair In France
May 04, 2012: Stallergenes Announces Positive Clinical Results For House Dust Mites Immunotherapy Tablet
Mar 21, 2012: Paladin Labs Receives Canadian Approval For Oralair
Dec 07, 2009: Stallergenes Announces Positive Three-Year Results Of Phase III Trial With Oralair
Nov 27, 2009: Stallergenes Receives European Marketing Authorization Approval For Oralair
Sep 17, 2009: Immunotherapy Tablet Containing Recombinant Allergen (rBet V 1) Of Birch Pollen: Positive Results For A Phase IIb/III Trial
Aug 27, 2009: Stallergenes Announces A Brand Name (ACTAIR) For The 2nd Sublingual Desensitization Tablet
Apr 29, 2009: Stallergenes Announces Positive Results From Phase IIb/III Clinical Trial Of House Dust Mites Desensitization Tablets
Jan 19, 2009: Oralair Grasses Obtains A Pediatric Market Authorisation In Germany
Financial Deals Landscape
Stallergenes S.A., Deals Summary
Stallergenes S.A., Pharmaceuticals & Healthcare, Deal Details
Private Equity
Ares Life Sciences Acquires An Additional 27.32% Stake In Stallergenes
Partnerships
Stallergenes Enters Into An Agreement With Solvay Pharma
Stallergenes Enters Into Distribution Agreement With Boryung Biopharma
Stallergenes Enters Into An Agreement With Catalent Pharma Solutions And The Medical House
Stallergenes Enters Into Co-Development Agreement With Protein'eXpert
Stallergenes Enters Into Joint Venture With Sanmed
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes
Licensing Agreements
Stallergenes Enters Into Licensing Agreement With Shionogi
Acquisition
Stallergenes Acquires Its UK-Based Distributor Medelo
Stallergenes Acquires Its Switzerland-Based Distributor Trimedal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Stallergenes S.A., Key Information
Stallergenes S.A., Key Facts
Stallergenes S.A. - Pipeline by Indication, 2012
Stallergenes S.A. - Pipeline by Stage of Development, 2012
Stallergenes S.A. - Monotherapy Products in Pipeline, 2012
Stallergenes S.A. - Filed, 2012
Stallergenes S.A. - Phase III, 2012
Stallergenes S.A. - Phase II, 2012
Stallergenes S.A. - Phase I, 2012
Stallergenes S.A. - Pipeline By Route of Administration, 2012
Stallergenes S.A. - Recent Pipeline Updates, 2012
Stallergenes S.A. - Dormant Developmental Projects,2012
Stallergenes S.A., Other Locations
Stallergenes S.A., Subsidiaries
Stallergenes S.A., Deals Summary
Ares Life Sciences Acquires An Additional 27.32% Stake In Stallergenes
Stallergenes Enters Into An Agreement With Solvay Pharma
Stallergenes Enters Into Distribution Agreement With Boryung Biopharma
Stallergenes Enters Into An Agreement With Catalent Pharma Solutions And The Medical House
Stallergenes Enters Into Co-Development Agreement With Protein'eXpert
Stallergenes Enters Into Joint Venture With Sanmed
Paladin Labs Enters Into Co-Marketing Agreement With Stallergenes
Stallergenes Enters Into Licensing Agreement With Shionogi
Stallergenes Acquires Its UK-Based Distributor Medelo
Stallergenes Acquires Its Switzerland-Based Distributor Trimedal
List of Figures
Stallergenes S.A. - Pipeline by Indication, 2012
Stallergenes S.A. - Pipeline by Stage of Development, 2012
Stallergenes S.A. - Monotherapy Products in Pipeline, 2012 9